Pitt researchers combine therapies to target aggressive childhood cancer

University of Pittsburgh researchers found that combining radiopharmaceutical therapy with CAR T-cell therapy significantly reduces tumors in high-risk neuroblastoma in preclinical models, indicating potential for treating other solid tumors in the future. Human trials are planned in at least two years pending further safety studies.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.